Skip to main content
SpringerLink
Log in

Prevention of cardiovascular disease

  • Chapter
Angiology in Practice

Part of the book series: Developments in Cardiovascular Medicine ((DICM,volume 187))

  • 100 Accesses

Abstract

Cardiovascular disease (CVD), including coronary heart disease (CHD), stroke, and occlusive peripheral arterial disease (PAD) remains the most common cause of mortality and morbidity despite the significant decline in the death rate during the last two decades both in Europe and the United States.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Tuomilehto J, Kuulasmaa K, Torppa J. WHO;MONICA project: Geographic Variation in mortality from cardiovascular disease. World Health Stat Q 1987;40:171–184.

    PubMed  CAS  Google Scholar 

  2. Uemura K. Pisa 2. Trends in cardiovascular disease mortality in industrialized countries since 1950. World Health Stat Q 1988;41:155–178.

    PubMed  CAS  Google Scholar 

  3. Uemura K. International trends in cardiovascular disease in the elderly. Eur Heart J 1988;9(Suppl.D):1–8.

    Article  PubMed  Google Scholar 

  4. American Heart Association. Heart and stroke facts 1944. Statistical supplement. Dallas: American Heart Association, 1993.

    Google Scholar 

  5. Pekkanen J, Linn S, Heiss G et al. Ten year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990;322:1700–1707.

    Article  PubMed  CAS  Google Scholar 

  6. Tsevat J, Weinstein MC, Williams LW, Tosteson ANA, Goldman L. Expected gains in life expectancy from various coronary heart disease risk modifications. Circulation 1991;83:1194–1201.

    Article  PubMed  CAS  Google Scholar 

  7. Vogel RA. Comparative clinical consequences of aggressive lipid management, coronary angioplasty and bypass surgery in coronary heart disease. Am J Cardiol 1992;69:1229–1233.

    Article  PubMed  CAS  Google Scholar 

  8. Haskell WL, Alderman EL, Fair JM et al. Effect of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). Circulation 1994;89:975–990.

    Article  PubMed  CAS  Google Scholar 

  9. Holman RL, McGill HC Jr, Strong JP, Geer JC. The natural history of atherosclerosis: The early aortic lesion as seen in New Orleans in the middle of the 20th Century. Am J Pathol 1958;34:209–235.

    PubMed  CAS  Google Scholar 

  10. PDAY Research Group. Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentration and smoking. A preliminary report from pathological determinants of atherosclerosis in youth (PDAY) research group. J Am Med Assoc 1990;264:3018–3024.

    Article  Google Scholar 

  11. Enos WF Jr, Beyer JC, Holmes RH. Pathogenesis of coronary disease in American soldiers killed in Korea. J Am Med Assoc 1955;158:912–914.

    Article  PubMed  Google Scholar 

  12. McNamara JJ, Molot MA, Stremple JF, Cutting RF. Coronary artery disease in combat casualties in Vietnam. J Am Med Assoc 1971;216:1185–1187.

    Article  CAS  Google Scholar 

  13. Newman WP III, Wattigney W, Berenson GS. Autopsy studies in United States. Children and adolescents: Relationship of risk factors to atherosclerotic lesions. Ann NY Acad Sci 1991;623:16–25.

    Article  PubMed  Google Scholar 

  14. Freedman DS, Newman WP III, Tracy RE et al. Black-white differences in aortic fatty streaks in adolescence and early adulthood. The Bogalusa Heart Study. Circulation 1988;77:856–864.

    Article  PubMed  CAS  Google Scholar 

  15. Strong JP. Landmark perspective coronary atherosclerosis in soldiers: A clue to the natural history of atherosclerosis in the young. J Am Med Assoc 1986;256:2863–2866.

    Article  CAS  Google Scholar 

  16. Dzan VJ, Gibbons GH, Cooke JP, Omugui N. Vascular biology and medicine in the 1990s. Scope concepts potention and perspective. Circulation 1993;87:705–719.

    Article  Google Scholar 

  17. Gibbon GH, Dzan VJ. The emerging concept of vascular remodeling. N Engl J Med 1993;330:1431–1438.

    Google Scholar 

  18. Ross R. The pathogenesis of atherosclerosis, a perspective for the 1990s. Nature 1993;362:801–809.

    Article  PubMed  CAS  Google Scholar 

  19. Levesque MJ, Nerem RM. The elongation and orientation of cultured endothelial cells in response to sheer stress. Biomech Eng 1985;107:341–347.

    Article  CAS  Google Scholar 

  20. Luscher TF. Imbalance of endothelium-derived relaxing and contracting factors. A new concept in hypertension. Am J Hypertens 1990;3:317–330.

    PubMed  CAS  Google Scholar 

  21. Van JR, Anggard EE, Boltingham R. Regulatory functions of the endothelium. N Engl J Med 1990;323:27–36.

    Article  Google Scholar 

  22. Flabahan NA, Vanhoutte PM. Endothelium-derived hyperpolarizing factor. Blood Vessels 1990;27:238–215.

    Google Scholar 

  23. Rader DJ, Hoeg JM, Brewer HB Jr. Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann Intern Med 1994;120:1012–1025.

    PubMed  CAS  Google Scholar 

  24. Racial (black and white) differences in serum lipoprotein (a) distribution and its relation to parental myocardial infarction in children. Bogalusa Heart Study. Circulation 1991;84:160–167.

    Google Scholar 

  25. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor. A meta-analysis and review of the literature. Ann Intern Med 1993;118:956–963.

    PubMed  CAS  Google Scholar 

  26. Mead TW, Mellows S, Brozovic N et al. Haemostatic function and ischaemic heart disease. Principle result of Northwick Park heart study. Lancet 1986;533–7.

    Google Scholar 

  27. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin J. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984;311:501–505.

    Article  PubMed  CAS  Google Scholar 

  28. Fuster V, Badimon L, Bardimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and acute coronary syndromes. N Engl J Med 1992;326:242–250.

    Article  PubMed  CAS  Google Scholar 

  29. Kannel WB, Wolf PA, Castelli WP, D’Agustino RB. Fibrinogen and risk of cardiovascular disease. The fibrinogen study. J Am Med Assoc 1987;258:1183–1186.

    Article  CAS  Google Scholar 

  30. Yarnell JW, Baker IA, Sweetman et al. Fibrinogen viscosity and white blood cell count are major risk factors for ischaemic heart disease. Circulation 1991;83:836–844.

    Article  PubMed  CAS  Google Scholar 

  31. Thompson SG, Kienast J, Pyke SDM, Haverkate F, Van de loo JCW. Haemostatic factors and the risk of myocardial or sudden death in patients with angina pectoris. N Engl J Med 1995;332:635–641.

    Article  PubMed  CAS  Google Scholar 

  32. Balleisen L, Schulte H, Assmann G, Epping PH, Van De Loo J. Coagulation factors and progress of coronary heart disease. Lancet 1987;1:461.

    Article  Google Scholar 

  33. Cremer P, Nagel D, Bottcher B, Seidel D. Fibrinogen ein koronarer risikofaktor. Diag Labor 1992;42:28–35.

    Google Scholar 

  34. Brunner EJ, Marmot MG, White IR et al. Gender and employment grade differences in blood cholesterol. Apolipoproteins and haemostatic factors in the Whitehall II study. Atherosclerosis 1993;102:195–207.

    Article  PubMed  CAS  Google Scholar 

  35. Nabulsi AA, Folsom AR, White A et al. For the atherosclerosis risk in communities study investigators. Association of hormone replacement therapy with various cardiovascular risk factors in post menopausal women. N Engl J Med 1993;328:1069–1075.

    Article  PubMed  CAS  Google Scholar 

  36. Rankinen T, Rauraman R, Vaeisanen S et al. An inverse relationship between physical activity and plasma fibrinogen in post menopausal women. Atherosclerosis 1993;102:181–186.

    Article  PubMed  CAS  Google Scholar 

  37. Wood PC, Yarnell JWG, Pickering J, Fehily AM, O’Brien JR. Exercise, fibrinogen and other risk factors for ischaemic heart disease. Caerphilly prospective heart disease study. Br Heart J 1993;69:183–187.

    Article  Google Scholar 

  38. Jaykody L, Kappagoda T, Senaratane MPJ, Thomson ABR. Impairment of endothelium dependent relaxation: An early marker of atherosclerosis in the rabbit. Br J Pharmacol 1988;94:335–346.

    Article  Google Scholar 

  39. Luscher TF, Richard V, Tschudi M, Yang Z, Boulanger C. Endothelial control of vascular tone in large and small coronary arteries. J Am Coll Cardiol 1990;15:519–527.

    Article  PubMed  CAS  Google Scholar 

  40. Harrison DG, Freiman PC, Armstrong MI, Marcus ML, Heisted DD. Alteration of vascular reactivity in atherosclerosis. Circ Res 1987;61(Suppl.II): 1174–1180.

    Google Scholar 

  41. Strom A, Jensen RA. Mortality from circulatory disease in Norway 1940–1945. Lancet 1951;1:126–129.

    Article  PubMed  CAS  Google Scholar 

  42. Multiple risk factor intervention research group. Multiple risk factor intervention trial: Risk factor changes and mortality results. N Engl J Med 1982;248:1465–1477.

    Google Scholar 

  43. Ornish D, Brown SE, Scherwitz LW et al. Can life style changes reverse coronary heart disease? Lancet 1990;336:129–133.

    Article  PubMed  CAS  Google Scholar 

  44. Schuler G, Hambrech R, Schlierf G et al. Regular physical exercise and low fat diet: Effects on progression of coronary artery disease. Circulation 1992;86:1–11.

    Article  PubMed  CAS  Google Scholar 

  45. Anderson KM, Wilson PWF, Odell PM, Kennel WB. An updated coronary risk profile: A statement for health professionals. Circulation 1991;83:356–362.

    Article  PubMed  CAS  Google Scholar 

  46. Muller C. Xanthomata, hypercholesterolaemia, angina pectoris. Acta Med Scand 1938;89:(Suppl.)75–84.

    Google Scholar 

  47. Thannhauser SJ, Magendantz H. The different clinical groups of xanthomatous disease: A clinical physiological study of 22 cases. Ann Intern Med 1938;11:1662–1746.

    CAS  Google Scholar 

  48. Goldbourt U, Yaari S. Cholesterol and heart disease mortality. A 23 year follow up study of 9902 men in Israel. Atherosclerosis 1990;10:512–519.

    CAS  Google Scholar 

  49. Pekkanen J, Nussinen A, Punsar S, Karvonen MJ. Short and long term association of serum cholesterol with mortality: The 25 year follow-up of the Finnish cohorts of the seven countries study. Am J Epidemiol 1992;135:1251–1258.

    PubMed  CAS  Google Scholar 

  50. Isles CG, Hole DJ, Gillis CR, Hawthorne VM, Lever AF. Plasma cholesterol coronary heart disease and cancer in the Renfrew and Paisley survey. Br Med J 1989:298;920–924.

    Article  CAS  Google Scholar 

  51. Leren P. The Oslo diet heart study. Eleven year report. Circulation 1970;42:935–942.

    Article  PubMed  CAS  Google Scholar 

  52. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. J Am Med Assoc 1975;231:360–381.

    Article  Google Scholar 

  53. Carlson LA, Danielson M, Ekberg I, Klintemar B, Rosenhamer G. Reduction of myocardial infarction by the combined treatment with Clofibrate and nicotinic acid. Atherosclerosis 1977;28:81–86.

    Article  PubMed  CAS  Google Scholar 

  54. Committee of principle investigator. A co-operative trial in the primary prevention of ischemic heart disease using Clofibrate. Br Heart J 1978;40:1069–1118.

    Article  Google Scholar 

  55. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results. J Am Med Assoc 1984;251:351–374.

    Article  Google Scholar 

  56. Frick MH, Elo O, Happa K et al. Helsinki Heart Study: Primary prevention with gemfibrozil in middle-aged men with dyslipaemia. N Engl J Med 1987;317:1237–1245.

    Article  PubMed  CAS  Google Scholar 

  57. Canner PL, Berge KG, Wenger NK et al. Fifteen year mortality in coronary drug project patients. Long term benefit with niacin. J Am Coll Cardiol 1986;8:1245–1255.

    Article  PubMed  CAS  Google Scholar 

  58. Buchwald H, Varlo RL, Matt JP et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolaemia. Report of the program on the surgical control of the hyperlipidemias (POSCH). N Engl J Med 1990;323:946–955.

    Article  PubMed  CAS  Google Scholar 

  59. Law MR, Wald NJ, Thompson SG. By how much and how quick does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? Br Med J 1994;308:367–373.

    Article  CAS  Google Scholar 

  60. Eleventh Bethesda Conference. Prevention of coronary heart disease. September 27–28, 1980. Bethesda, Maryland. Am J Cardiol 1981;47:713–776.

    Google Scholar 

  61. Pyorala K, Backer DE, Graham I, Pool Wilson P. Wood D. On behalf of the task force prevention of coronary heart disease in clinical practice. Eur Heart J 1994;15:1300–1331.

    PubMed  CAS  Google Scholar 

  62. Prevention of coronary heart disease, report of WHO expert committee. WHO technical report series 678. Geneva: World Health Organisation, 1982.

    Google Scholar 

  63. US Surgeon General. Cardiovascular disease, the health consequences of smoking. Washington, DC: US Department of Health and Human Services, Public Health Service, Office on Smoking and Health, 1983 (DHHS publication no. (PHS) 84-50204-384P).

    Google Scholar 

  64. US Surgeon General. Reducing the consequences of smoking: 25 years of progress. Bethesda, MD: US Department of Health and Human services, Public Health Services, Office on Smoking and Health, 1989 (DHSS publication no. (CDC) 89-8411. 703P).

    Google Scholar 

  65. Willett WC, Green A, Stampler MJ et al. Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes. N Engl J Med 1987;317:1303–1309.

    Article  PubMed  CAS  Google Scholar 

  66. Lacroix AZ, Lang J, Scherr P et al Smoking and mortality among older men and women in three communities. N Engl J Med 1991;324:1614–1625.

    Article  Google Scholar 

  67. Wolf PA, D’Agostino RB, Kännel WB, Bonita R, Belanger AJ. Cigarette smoking as a risk factor for stroke. The Framingham Study. J Am Med Assoc 1988;259:1025–1029.

    Article  CAS  Google Scholar 

  68. Liedberg E, Person BM. Age, diabetes and smoking in lower limb amputations for arterial occlusive disease. Acta Orthop Scand 1983;54:383–388.

    Article  PubMed  CAS  Google Scholar 

  69. Strachan DP. Predictors of death from aortic aneurysm among middle aged men. The Whitehall Study. Br J Surg 1991;78:401–404.

    Article  PubMed  CAS  Google Scholar 

  70. Jonas MA, Oates JA, Ockene JK, Hennekens CH. AHA position statement. Statement on smoking and cardiovascular disease for health care professionals. Circulation 1992;86:1664–1669.

    Article  PubMed  CAS  Google Scholar 

  71. Hensen EF, Andersen LT, Von Eyben FE. Cigarette smoking and age at first acute myocardial infarction and influence of gender and extent of smoking. Am J Cardiol 1993;71:1439–1442.

    Article  Google Scholar 

  72. Keys A, (ed.). Seven countries. A multivariate analysis of death and coronary heart disease. Cambridge, MA: Harvard University Press, 1980.

    Google Scholar 

  73. Coultas DB, Stidley CA, Samet JM. Cigarette yields of tar and nicotine and marker of exposure to tobacco smoke. Am Rev Respit Dis 1993;148:435–440.

    CAS  Google Scholar 

  74. Negri E, Franzosi MG, La Vecchia C, Santoro L, Nobili A, Tognoni G, on behalf of Gissi — E FRIM Investigators. Tar yield of cigarette and risk of acute myocardial infarction. Br Med J 1993;306:1567–1570.

    Article  CAS  Google Scholar 

  75. Fiore MC, Jorenby DE, Baker TB, Kenford SL. Tobacco dependence and the nicotine patch. Clinical guidelines for effective use. J Am Med Assoc 1992;268:2687–2694.

    Article  CAS  Google Scholar 

  76. Imperial cancer research fund general Research Group. Effectiveness of nicotine patch in helping people stop smoking. Results of a randomized trial in general practice. Br Med J 1993;306:1304–1308.

    Article  Google Scholar 

  77. Russell MAH, Stapleton JA, Teyerabend C et al. Targeting heavy smokers in general practice. Randomized control trial of transdermal nicotine patches. Br Med J 1993;306:1309–1312.

    Google Scholar 

  78. Kannel WB, Dawber TR, McGee DL. Perspective on systolic hypertension. The Framingham Study. Circulation 1980;61:1179–1182.

    Article  PubMed  CAS  Google Scholar 

  79. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic and cardiovascular risks. Arch Intern Med 1993;153:598–615.

    Article  PubMed  CAS  Google Scholar 

  80. SHEP Co-operative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program (SHEP). J Am Med Assoc 1991;265:3255–3264.

    Article  Google Scholar 

  81. The Joint National Committee on detection, evaluation and treatment of high blood pressure. The fifth report of the Joint National Committee on detection, evaluation and treatment of high blood pressure. Bethesda National Institute of health. National heart lung and blood institute. NIH publication 93-1088, 1993.

    Google Scholar 

  82. Hoes AW, Grobbee DE, Lubsen J. Does drug treatment improve survival? Reconciling the trials in mild to moderate hypertension. Hoes AW. Non potassium sparing diuretics and sudden cardiac death in hypotensive patients, pharmacoepidemiological approach. Thesis, Erasmus University, Rotterdam, 1992.

    Google Scholar 

  83. Hebert PR, Moser M, Mayer J, Glynn RJ, Hennekens CH. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med 1993:578–81.

    Google Scholar 

  84. Lace J, Antmann EM, Silva JJ, Kupelnick B, Mosteller F, Chalmers JC. Cumulative meta-analysis of theraputic trials for myocardial infarction. N Engl J Med 1992;327:248–254.

    Article  Google Scholar 

  85. Christleib AR. Treatment selection consideration for the hypertensive diabetic patient. Arch Intern Med 1990;150:1167–1174.

    Article  Google Scholar 

  86. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long term stabilizing effect of angiotensin converting enzyme inhibitors on plasma creatinine and proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993;118:577–581.

    PubMed  CAS  Google Scholar 

  87. Magenson CE. Angiotensin converting enzyme inhibitors and diabetic nephropathy. Br Med J 1992;304:327.

    Article  Google Scholar 

  88. Groden DL. Vasodilator therapy for congestive heart failure, lessons from mortality trials. Arch Intern Med 1993;153:445–454.

    Article  PubMed  CAS  Google Scholar 

  89. Maskin CS. Aerobic exercise training in cardiopulmonary disease. In: Weber KT, Janicki JS (eds), Cardiopulmonary exercise testing. Physiological principles and clinical applications. Philadelphia: Saunders, 1986:317–332.

    Google Scholar 

  90. Bittner V, Oberman A. Efficacy studies in coronary rehabilitation. Cardiol Clin 1993;11:333–347.

    PubMed  CAS  Google Scholar 

  91. Hedbaeck B, Perk J, Woldin P. Long term reduction of cardiac mortality after myocardial infarction. 10 year results of a comprehensive rehabilitation programme. Eur Heart J 1993;14:831–835.

    Article  Google Scholar 

  92. Van Itallie TB. Obesity: Adverse effect on health and longevity. Am J Clin Nutl 1979;32(Suppl.):2723–2733.

    Google Scholar 

  93. Hambrecht R, Niebauer J, Marburger C et al. Various intensities of leisure time physical activity in patients with coronary artery disease. Effect on cardiorespiratory fitness and progression of atherosclerotic leasions. J Am Coll Cardiol 1993;22:468–477.

    Article  PubMed  CAS  Google Scholar 

  94. Bierman EL, Hirsch J. Obesity. In: Williams RH (ed.), Textbook of endocrinology. 6th ed. Vol I. Philadelphia: Saunders, 1981:906–921.

    Google Scholar 

  95. Mann GV. The influence of obesity on health. N Engl J Med 1974;291:178–185, 226–32.

    Article  PubMed  CAS  Google Scholar 

  96. Lew EA, Gardinkel L. Variations in mortality by weight among 750 000 men and women. J Chronic Dis 1979;32:563–576.

    Article  PubMed  CAS  Google Scholar 

  97. Hubert HB, Feinleib, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease. A 26 year follow-up of participants in the Framingham heart study. Circulation 1983;67:968–977.

    Article  PubMed  CAS  Google Scholar 

  98. Simopolous AP, Van Itallie TB. Bodyweight health and longevity. Ann Intern Med 1984;100:285–295.

    Google Scholar 

  99. Manson JE, Celditz GA, Stampler MJ et al. A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med 1990;322:882–889.

    Article  PubMed  CAS  Google Scholar 

  100. Kissebah AH, Vydelingum N, Murray R et al. Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 1982;54:254–260.

    Article  PubMed  CAS  Google Scholar 

  101. Krotkiewski M, Bjorntorp P, Sjostrom L, Smith U. Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution. J Clin Invest 1983;72:1150–1162.

    Article  PubMed  CAS  Google Scholar 

  102. Bjorntrop P. Regional patterns of fat distribution. Ann Intern Med 1985;103:994–995.

    Google Scholar 

  103. Wood PD, Stefanick ML, Dreon DM et al. Change in plasma lipid and lipoproteins in overweight men during weight loss through dieting as compared with exercise. N Engl J Med 1988;319:1173–1179.

    Article  PubMed  CAS  Google Scholar 

  104. Committee on diet and health. Diet and health implication for reducing chronic disease risk. Washington, DC: National Academy Press, 1989.

    Google Scholar 

  105. Dwyer JT. Treatment of obesity. In: Bjorntorp P, Porodoff BN (eds), Conventional programme and fat-diet in obesity. Philadelphia: JB Lippincott, 1992:662–676.

    Google Scholar 

  106. Bjorntorp P. Physical exercise in treatment of obesity. Philadelphia: JB Lippincott, 1992:708–711.

    Google Scholar 

  107. Chen Z, Peto R, Collins R, MacMahon S, Luj, LIW. Serum cholesterol and coronary heart disease in population with low cholesterol. Br Med J 1991;303:276–282.

    Article  CAS  Google Scholar 

  108. Menotti A, Keys A, Krumhout D et al. Inter cohort differences in coronary heart disease mortality in the 25 year follow-up of the Seven Countries Study. Eur J Epidemiol 1993;9:527–536.

    Article  PubMed  CAS  Google Scholar 

  109. Verschuren WM, Jacobs DR, Bloemberg BP et al Serum total cholesterol and long-term coronary heart disease mortality in different cultures. J Am Med Assoc 1995;274:131–136.

    Article  CAS  Google Scholar 

  110. Summary of the second report of the National Cholesterol Education Program (NCEP): Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel II). J Am Med Assoc 1993;269:3015–3023.

    Article  Google Scholar 

  111. Ragland DR, Brand RJ. Coronary heart disease mortality in western collaborative group study follow-up experience of 22 years. Am J Epidemiol 1988;127:462–475.

    PubMed  CAS  Google Scholar 

  112. Neaton JD, Blackburn H, Jacobs D et al. Serum cholesterol level and mortality findings for men screened in the multiple risk factor intervention trial. Arch Intern Med 1992;152:1490–1500.

    Article  PubMed  CAS  Google Scholar 

  113. Davey-Smith G, Shipley MJ, Marmot MG, Rose G. Plasma cholesterol and mortality. The Whitehall Study. J Am Med Assoc 1992;267:70–76.

    Article  Google Scholar 

  114. Chenz, Peto R, Collins R, MacMahon S, Luj, LIW. Serum cholesterol concentration and coronary heart disease in a population with low serum cholesterol concentration. Br Med J 1991;303:276–282.

    Article  Google Scholar 

  115. Ulvenstram G, Bergstrand R, Johansson S et al. Prognostic importance of cholesterol levels after myocardial infarction. Prev Med 1984;13:355–366.

    Article  Google Scholar 

  116. Pekkanen J, Linn S, Heiss J et al. 10 years mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990;322:1700–1707.

    Article  PubMed  CAS  Google Scholar 

  117. Wong ND, Wilson PWF, Kannel WB. Serum cholesterol as a prognostic factor after myocardial infarction. The Framingham Study. Ann Intern Med 1991;115:687–693.

    PubMed  CAS  Google Scholar 

  118. Yusuf S, Wittes J, Friedman L. Overview of results of randomised clinical trials in heart disease II. Unstable angina, heart failure, primary prevention with aspirin and risk factor modification. J Am Med Assoc 1988;260:2259–2263.

    Article  CAS  Google Scholar 

  119. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S). Lancet 1944;344:1383–1389.

    Google Scholar 

  120. Miller GJ, Miller NE. Plasma high density lipoprotein concentration and development of ischaemic heart disease. Lancet 1975;1:16–19.

    Article  PubMed  CAS  Google Scholar 

  121. Miller NE, Forde OH, Thelle DS, MJQS OD. The Tromso heart study of high density lipoprotein and coronary heart disease — prospective case control study. Lancet 1977;1:965–968.

    Article  PubMed  CAS  Google Scholar 

  122. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. Am J Med 1977;62:707–714.

    Article  PubMed  CAS  Google Scholar 

  123. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. J Am Med Assoc 1986;256:2835–2838.

    Article  CAS  Google Scholar 

  124. Sherwin RW, Wentworth DN, Cutler JA, Hulley SB, Kuller LH, Stamler J. Serum cholesterol levels and cancer mortality in 301, 662 men screened for the multiple risk factor intervention trial. J Am Med Assoc 1987;257:943–948.

    Article  CAS  Google Scholar 

  125. Jacobs DR Jr, Mebane IL, Bangdiwala SI, Criqui MH, Tyroler HA. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women. The follow-up study of the lipid research clinic prevalence study. Am J Epidemiol 1990;131:32–47.

    PubMed  Google Scholar 

  126. Manninen V, Elo MO, Frick H et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. J Am Med Assoc 1988;260:641–651.

    Article  CAS  Google Scholar 

  127. Robinson D, Fern JA, Bevan EA, Stock J, Williams PT, Galton DJ. High density lipoprotein subfractions and coronary risk factors in normal men. Arteriosclerosis 1987;7:341–346.

    Article  PubMed  CAS  Google Scholar 

  128. Haffner SM, Applebaum-Bowden D, Wahl PW et al. Epidemiological correlates of high density lipoprotein subfraction apolipoproteins, A-I, A-II and D, and lecithin cholesterol acetyl transferase E: Effect of smoking, alcohol and adiposity. Anteriosclerosis 1985;5:169–177.

    Article  CAS  Google Scholar 

  129. Criqui MH, Heiss G, Cohn K et al. Plasma triglyceride level and mortality from coronary heart disease. New Engl J Med 1993;328:1220–1225.

    Article  PubMed  CAS  Google Scholar 

  130. Austin MA. Plasma triglycerides as a risk factor for coronary heart disease: The epidemiologic evidence and beyond. Am J Epidemiol 1989;129:249–257.

    PubMed  CAS  Google Scholar 

  131. Barbir M, Wile D, Tayner I, Aber VR, Thompson GR. High prevelance of hypertriglyceridaemia and apolipoprotein abnormalities in coronary artery disease. Br Heart J 1988;60:397–403.

    Article  PubMed  CAS  Google Scholar 

  132. Pocock SJ, Shaper AG, Philips AN. Concentration of high density lipoprotein cholesterol, triglycerides and total cholesterol in ischaemic heart disease. Br Med J 1989;298:998–1002.

    Article  CAS  Google Scholar 

  133. Assmann G, Schulte H. Triclycerides and atherosclerosis: Results from the prospective cardiovascular munster study. In: Gotto AM Jr, Paoletti R (eds), Atherosclerosis reviews Vol. 22. New York: Raven Press, 1991:51–57.

    Google Scholar 

  134. Wilson PWF, Anderson KM, Castelli WP. The impact of triglycerides on coronary heart disease: The Framingham Study. In: Gotto AM Jr, Paoletti R (eds), Atherosclerosis reviews Vol. 22. New York: Raven Press, 1991:59–63.

    Google Scholar 

  135. Rhoads GG, Gulbrandsen CL, Kagan A. Serum lipoproteins and coronary heart disease in a population study of Hawaii Japanese men. N Engl J Med 1976;294(6):293–298.

    Article  PubMed  CAS  Google Scholar 

  136. Davis CE, Gordon D, LaRosa J, Wood PD, Halperin M. Correlations of plasma high density lipoprotein cholesterol level with other plasma lipids and lipoprotein concentrations: The lipid research clinics programme prevalence study. Circulation 1980;62(4pt2):24–30.

    CAS  Google Scholar 

  137. Albrink MJ, Krauss RM, Lindgren FT, Vonder Groeben J, Pan S, Wood PD. Inter correlations among high density lipoprotein, obesity and triglycerides in a normal population. Lipids 1980;15:668–678.

    Article  PubMed  CAS  Google Scholar 

  138. Grundy SM, Vega GL. Two different views of the relationship of hypertriglyceridemia to coronary heart disease. Arch Intern Med 1992;152:28–34.

    Article  PubMed  CAS  Google Scholar 

  139. Heinrich J, Sankamp M, Kokott R, Schulte H, Assmann G. Relationship of lipoprotein (a) to variables of coagulation and fibrinolysis in a healthy population. Clin Chem 1991;37:1950–1954.

    PubMed  CAS  Google Scholar 

  140. West KM. Epidemiology of diabetes and its vascular lesions. New York: Elsevier, 1978.

    Google Scholar 

  141. Butler WJ, Ostrander LD Jr, Carman WJ, Lamphiear DE. Mortality from coronary heart disease in the Tecumseh study: Long term effect of diabetes mellitus, glucose tolerance and other risk factors. Am J Epidemiol 1985;121:541–547.

    PubMed  CAS  Google Scholar 

  142. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factor for cardiovascular disease. The Framingham Study. Diabetes Care 1979;2:120–126.

    Article  PubMed  CAS  Google Scholar 

  143. Heyden S, Heiss G, Bartel AG, Harnes CG. Sex differences in coronary mortality among diabetics in Evans County, Georgia. J Chronic Dis 1980;33:265–273.

    Article  PubMed  CAS  Google Scholar 

  144. Barrett-Connor E, Wingard DL. Sex differential in ischaemic heart disease mortality in diabetics. A prospective population based study. Am J Epidemiol 1983;118:489–496.

    PubMed  CAS  Google Scholar 

  145. Morrish NJ, Stevens LK, Head J, Fuller JH, Jarrett RJ, Keen H. A prospective study of mortality among middle-aged diabetic patients (the London cohort of the WHO multi-national study of vascular disease in diabetics). II Associated risk factors. Diabetologia 1990;33:542–548.

    Article  PubMed  CAS  Google Scholar 

  146. Krolewski AS, Warram JH, Rand LI et al. Epidemiologic approach to the etiology of type I diabetes mellitus and its complications. N Engl J Med 1987;317:1390–1398.

    Article  PubMed  CAS  Google Scholar 

  147. Krolewski AS, Kosinski EJ, Warram JH et al. Magnitude and determinants of coronary artery disease in juvenile onset, insulin dependent diabetes mellitus. Am J Cardiol 1987;59:750–755.

    Article  PubMed  CAS  Google Scholar 

  148. Manson JE Colditz GA, Stampler MJ et al. A prospective study of maturity onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 1991;151:1141–1147.

    Article  PubMed  CAS  Google Scholar 

  149. Pan WH, Cedres LB, Liu K et al. Relationship of clinical diabetes and asymptomatic hyper-glycaemia to risk of coronary heart disease mortality in men and women. Am J Epidemiol 1986;123:504–516.

    PubMed  CAS  Google Scholar 

  150. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham Study. J Am Med Assoc 1979;241:2035–2038.

    Article  CAS  Google Scholar 

  151. Jarrett RJ. The epidemiology of coronary heart disease and related factors in the context of diabetes mellitus and impaired glucose tolerance. In: Jarrett RJ (ed.), Diabetes and heart disease. Amsterdam: Elsevier, 1984:1–23.

    Google Scholar 

  152. Renderman NB, Handenschild C. Diabetes as an atherogenic factor. Prog Cardiovasc Dis 1984;26:373–412.

    Article  Google Scholar 

  153. Fleischer N, Fein FS, Sonnenblick EH. The heart and endocrine disease. In: Hurst JW (ed.), The heart arteries and veins. 7th ed. New York: McGraw-Hill, 1990:1497–1513.

    Google Scholar 

  154. Chakratti R, Meade TW. WHO multination group, clotting factors, platelet function and fibrinolytic activity in diabetics and in a comparison group. Diabetologia 1976;12:383 (Abstract).

    Article  Google Scholar 

  155. Mayne EE, Bridges JM, Weaver JA. Platelet adhesiveness, plasma fibrinogen and factor 8 levels in diabetes mellitus. Diabetologia 1970;6:436–440.

    Article  PubMed  CAS  Google Scholar 

  156. DCCT Research Group. Diabetes control and complication trial (DCCT) results of feasibility study. Diabetes Care 1987;10:1–19.

    Article  Google Scholar 

  157. Kannel WB. Lipids, diabetes and coronary heart disease. Insights from the Framingham Study. Am Heart J 1985;110:1100.

    Article  PubMed  CAS  Google Scholar 

  158. Rosengren A, Wellin L, Tsipogianni A, Wilhelmsen L. Impact of cardiovascular risk factors on coronary heart disease and mortality among middle aged diabetic men. A general population study. Br Med J 1989;299:127–131.

    Article  Google Scholar 

  159. Manson JE, Golditz GA, Stampfer MJ et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 1991;151:1141–1147.

    Article  PubMed  CAS  Google Scholar 

  160. Stamler J, Vaccaro O, Neaton J, Wentworth D for the multiple risk factor intervention trial research group. Diabetes, other risk factors and 12 years cardiovascular mortality for men screened for the multiple risk factor intervention trial. Diabetes Care 1993;16:434–449.

    Article  PubMed  CAS  Google Scholar 

  161. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larson B, Welin L, Tibblin J. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984;311:501–505.

    Article  PubMed  CAS  Google Scholar 

  162. Mead TW, Mellow S, Brozovic M et al. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park hospital study. Lancet 1986;ii:533–537.

    Article  Google Scholar 

  163. Kannel WB, Wolf PA, Castelli WP, D’Agostino RB. Fibrinogen and risk of cardiovascular disease. J Am Med Assoc 1987;258:1183–1186.

    Article  CAS  Google Scholar 

  164. Meade TW. Fibrinogen and other clotting factors in cardiovascular disease. In: Francis RB Jr (ed.), Atherosclerotic vascular disease, haemostatis and endothelial function. New York: Marcel Dekker, 1992:1–34.

    Google Scholar 

  165. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor. A meta-analysis and review of the literature. Ann Intern Med 1993;118:956–963.

    PubMed  CAS  Google Scholar 

  166. Thaullow E, Erikssen J, Sandvik K-L et al. Blood platelets count and function related to total and cardiovascular health in apparently healthy men. Circulation 1991;84:613–617.

    Article  Google Scholar 

  167. Elwood PC, Renaud S, Sharp DS, Beswick AD, O’Brien Jr, Yarnell JW. Ischaemic heart disease and platelets aggregation. The Caerphilly collaborative heart disease study. Circulation 1991;83:38–44.

    Article  PubMed  CAS  Google Scholar 

  168. Antiplatelets Trialist Collaboration. Collaborative overview of randomized trials of antiplatets therapy — I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelets therapy in various categories of patients. Br Med J 1994;308:81–106.

    Article  Google Scholar 

  169. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47–63.

    Article  PubMed  CAS  Google Scholar 

  170. Stampfer MJ, Colditz GA, Willett WC et al. Postmenopausal estrogen therapy and cardiovascular disease: Ten-year follow up from the nurses health study. N Engl J Med 1991;325:756–762.

    Article  PubMed  CAS  Google Scholar 

  171. Wilson PWF, Garrison RJ, Castelli WP. Post menopausal estrogen use, cigarette smoking and cardiovascular morbidity in women over 50: The Framingham Study. N Engl J Med 1985;313:1038–1043.

    Article  PubMed  CAS  Google Scholar 

  172. Henderson BE, Ross RK, Paganini-Hill A, Mack TM. Estrogen use and cardiovascular disease. Am J Obstet Gynecol 1986;154:1181–1186.

    PubMed  CAS  Google Scholar 

  173. Bush TL, Miller VT. Effects of pharmacologic agents used during menopause. Impact on lipids and lipoproteins. In: Mishell DR JR (ed.), Menopause: Physiology and pharmacology. Chicago: Year Book Medical Publishers, 1987:187–208.

    Google Scholar 

  174. Lobo RA. Estrogen and cardiovascular disease. Ann NY Acad Sci 1990;592:286–294.

    Article  PubMed  CAS  Google Scholar 

  175. Belchetz PE. Hormonal treatment of postmenopausal women. N Engl J Med 1994;330:1062–1071.

    Article  PubMed  CAS  Google Scholar 

  176. Soma M, Fumangalli R, Paoleti R et al. Plasma Lp (a) concentration after estrogen and progestragen in post menopausal women. Lancet 1991;337:612.

    Article  PubMed  CAS  Google Scholar 

  177. Hegele RA. Lipoprotein (a): An emerging risk factor for atherosclerosis. Can J Cardiol 1989;5:263–265.

    PubMed  CAS  Google Scholar 

  178. Fischer GM, Cherian K, Swain ML. Increased synthesis of aortic collagen and elastin in experimental atherosclerosis. Inhibition by contraceptive steroid. Atherosclerosis 1981;39:463–467.

    Article  PubMed  CAS  Google Scholar 

  179. La Rosa JC. Estrogen: Risk versus benefit for the prevention of coronary artery disease. Coronary Artery Dis 1993;4:588–594.

    Article  Google Scholar 

  180. Chang WC, Nakao J, Orimo H, Murota S-I. Stimulation of prostaglandin cyclo-oxygenase and synthetase activities by estradiol in rat aortic smooth muscle cells.

    Google Scholar 

  181. Sack MN, Rader DJ, Cannon RO. Oestrogen and inhibition of oxidation of low-density lipoproteins in post-menopausal women. Lancet 1994;243:269–270.

    Article  Google Scholar 

  182. Haarbo J, Leth-Espensen P, Stender S, Christiansen C. Estrogen monotherapy and combined estrogen-progestogen replacement therapy attenuates aortic accumulation of cholesterol in ovariectomized cholesterol fed rabbits. J Clin Invest 1991;87:1274–1279.

    Article  PubMed  CAS  Google Scholar 

  183. Coronary Drug Project Research Group. Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N Engl J Med 1980;303:1038–1041.

    Article  Google Scholar 

  184. Rosenberg L, Armstrong B, Jick H. Myocardial infarction and estrogen therapy in post menopausal women. N Engl J Med 1976;294:1256–1259.

    Article  PubMed  CAS  Google Scholar 

  185. Rosenberg L, Slone D, Shapiro S, Kaufmann D, Strolley PD, Miettinen. Non contraceptive estrogens and myocardial infarction in young women. J Am Med Assoc 1980;244:339–342.

    Article  CAS  Google Scholar 

  186. Jick H, Dinah B, Rothman KJ. Non contraceptive estrogens and non fatal myocardial infarction. J Am Med Assoc 1978;239:1407–1408.

    Article  CAS  Google Scholar 

  187. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. J Am Med Assoc 1991;265:1861–1867.

    Article  CAS  Google Scholar 

  188. Ernster VL, Bush TL, Huggins GR, Hulka BS, Kelsey JL, Schottenfeld D. Benefits and risks of menopausal estrogen and/or progestin hormone use. Prev Med 1988;17:201–223.

    Article  PubMed  CAS  Google Scholar 

  189. Hennekens CH. Alcohol. In: Kaplan N, Stamler J (eds), Prevention of coronary heart disease, practical management of the risk factors. Philadelphia: Saunders, 1983:130–138.

    Google Scholar 

  190. Kannel WB, Gordon T. Some characteristics of the incidence of cardiovascular disease and health. Framingham Study: 16 year follow-up. Section 26 of the Framingham Study. Washington, DC: Government Printing Office, 1970.

    Google Scholar 

  191. Yano K, Rhoads GG, Kagan A. Coffee, alcohol and risk of coronary heart disease among Japanese men living in Hawaii. N Engl J Med 1977;297:405–409.

    Article  PubMed  CAS  Google Scholar 

  192. Stampfer MJ, Colditz GA, Willett EC, Speizer FE, Hennekens CH. A prospective study of moderate alcohol consumption and the risk of coronary disease and stroke in women. N Engl J Med 1988;319:267–273.

    Article  PubMed  CAS  Google Scholar 

  193. Rimm EB, Giovannucci EL, Willett WC et al. A prospective study of alcohol consumption and risk of coronary disease in men. Lancet 1991;338:464–468.

    Article  PubMed  CAS  Google Scholar 

  194. Hennekens CH, Willett W, Rosner B, Cole DS, Mayrent SL. Effects of beer, wine, liquor on coronary deaths. J Am Med Assoc 1979;242:1973–1974.

    Article  CAS  Google Scholar 

  195. Thornton J, Symes C, Heaton K. Moderate alcohol intake reduces bile cholesterol saturation and raises HDL cholesterol. Lancet 1983;2:819–822.

    Article  PubMed  CAS  Google Scholar 

  196. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol apolipoproteins and the risk of myocardial infarction. N Engl J Med 1991;325:373–381.

    Article  PubMed  CAS  Google Scholar 

  197. Buring JE, O’Connor GT, Goldhaber SZ et al. Decreased HDL2 and HDL3 cholesterol Apo A-I and Apo A-II and increased risk of myocardial infarction. Circulation 1992;95:22–29.

    Article  Google Scholar 

  198. Toivanen J, Ylikorkalo O, Vinikkal. Ethanol inhibits platelets’ thromboxane A2 production but has no effect on lung prostacyclin synthesis in humans. Thromb Res 1984;33:1–8.

    Article  PubMed  CAS  Google Scholar 

  199. Laing WE. Ethyl alcohol enhances plasminogen activation secretion by endothelial cells. J Am Med Assoc 1983;250:772–776.

    Article  Google Scholar 

  200. Steering Committee of the Physicians Health Study research group. Final report on the aspirin component of the ongoing Physicians Health Study. N Engl J Med 1989;321:129–135.

    Article  Google Scholar 

  201. Peto R, Gray R. Collins R et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J 1988;296:313–316.

    Article  CAS  Google Scholar 

  202. Hennekens CH, Peto R, Hutchinson GB, Doll R. An overview of the the British and American aspirin studies. N Engl J Med 1988;318:923–924.

    Article  PubMed  CAS  Google Scholar 

  203. ISIS-2 Collaborative Group. Randomised trial of IV streptokinase, oral aspirin, both or neither among 17187 cases of suspected acute myocardial infarction. Lancet 1988;ii:349–360.

    Google Scholar 

  204. Antiplatelets Trialists’s collaboration. Secondary prevention of vascular disease by prolonged antiplatelets treatment. Br Med J 1988;269:320–331.

    Article  Google Scholar 

  205. Yousuf S, Sleight P, Held P, McMahon S. Routine medical management of acute myocardial infarction: Lessons from overviews of recent randomised controlled trials. Circulation 1990;82(Suppl.II):117–134.

    Google Scholar 

  206. Yusuf S, Witters J, Friedman L. Overview of results of randomised clinical trials in heart disease. I. Treatments following myocardial infarction. J Am Med Assoc 1988;260:2088–2093.

    Article  CAS  Google Scholar 

  207. The Consensus Trial Study Group. Effect of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987;316:1429–1435.

    Article  Google Scholar 

  208. The SOLVD Investigations. Effect of enalapril on survival in patients with reduced left ventricular ejections and congestive heart failure. N Engl J Med 1991;325:293–302.

    Article  Google Scholar 

  209. The SOLVD Investigations. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685–691.

    Article  Google Scholar 

  210. ISIS IV. Collaborative group. ISIS-4 (Fourth international study of infarct survival): Randomised study of oral Captopril in over 50000 patients with suspected acute myocardial infarction. Circulation 1993;88:1394 (Abstract).

    Google Scholar 

  211. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H on behalf of the Consensus II Study Group. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the North Scandinavian Enalapril Survival Study (Consensus II). N Engl J Med 1992;327:678–684.

    Article  PubMed  CAS  Google Scholar 

  212. The acute infarction ramipril efficacy (AIRE) study investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821–828.

    Google Scholar 

  213. Yusuf S, Pepine CJ, Garces C et al. Effect of enalapril on myocardial infarction and unstable angina pectoris in patients with low ejection fractions. Lancet 1922;340:1173–1178.

    Article  Google Scholar 

  214. Pfeffer MA, Poranunwald E, Moye LA et al. on behalf of SAVE Investigations. Effect of Captopril on mortality and morbidity in patients with left ventricular dysfunction after acute myocardial infarction: Results of survival and ventricular enlargement trial. N Engl J Med 1992;327:669–677.

    Article  PubMed  CAS  Google Scholar 

  215. Yusuf S, Peto J, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: An overview of the randomised trials. Prog Cardiovas Dis 1985;27:335–371.

    Article  CAS  Google Scholar 

  216. Stampfer MJ, Hennekens CH, Manson JAE, Goldlitz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993;328:1444–1449.

    Article  PubMed  CAS  Google Scholar 

  217. Rimm EB, Stampfer MJ, Ascherio A, Giuvahnucci E, Coldlitz GA, Willett WC. Vitamin E consumption and risk of coronary disease in men. N Engl J Med 1993;328:1450–1456.

    Article  PubMed  CAS  Google Scholar 

  218. Kardinaal AFM, Kok FJ, Kinstad J et al. Antioxidants in adipose tissue and risk of myocardial infarction: The Euramic Study. Lancet 1993;342:1379–1384.

    Article  PubMed  CAS  Google Scholar 

  219. Moller JH, Taubert KA, Allen HD et al. Cardiovascular health and disease in children. Current status. Circulation 1984;89:923–930.

    Article  Google Scholar 

Download references

Authors
  1. Mahmoud Barbir
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fawzi Lazem
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Charles Ilsley
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Cardiology, Central Middlesex Hospital, London, UK

    Abdul-Majeed Salmasi

  2. Department of Internal Medicine, University ‘Tor Vergata’ of Rome, Rome, Italy

    Antonio Strano

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Barbir, M., Lazem, F., Ilsley, C. (1996). Prevention of cardiovascular disease. In: Salmasi, AM., Strano, A. (eds) Angiology in Practice. Developments in Cardiovascular Medicine, vol 187. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-5406-2_35

Download citation

  • DOI: https://doi.org/10.1007/978-94-011-5406-2_35

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-6274-9

  • Online ISBN: 978-94-011-5406-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation